DC Funds’s Barinthus Biotherapeutics BRNS Stock Holding History

DC Funds’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$365K	Hold	642,204	–	–	24.59%	3
2025 Q4	$450K	Hold	642,204	–	–	30.95%	2
2025 Q3	$803K	Hold	642,204	–	–	25.81%	3
2025 Q2	$597K	Hold	642,204	–	–	27.74%	3
2025 Q1	$625K	Hold	642,204	–	–	30.22%	2
2024 Q4	$776K	Hold	642,204	–	–	21.77%	3
2024 Q3	$764K	Hold	642,204	–	–	14.84%	3
2024 Q2	$899K	Hold	642,204	–	–	14.93%	3
2024 Q1	$1.53M	Hold	642,204	–	–	14.77%	3
2023 Q4	$2.37M	Hold	642,204	–	–	28.49%	2
2023 Q3	$1.98M	Hold	642,204	–	–	40.85%	1
2023 Q2	$1.32M	Hold	642,204	–	–	28.18%	3
2023 Q1	$1.44M	Hold	642,204	–	–	33.51%	2
2022 Q4	$1.51M	Hold	642,204	–	–	40.86%	1
2022 Q3	$2.06M	Hold	642,204	–	–	30.98%	2
2022 Q2	$2.86M	Hold	642,204	–	–	39.43%	1
2022 Q1	$3.34M	Hold	642,204	–	–	43.39%	1
2021 Q4	$7.13M	Hold	642,204	–	–	42.25%	1
2021 Q3	$10.1M	Hold	642,204	–	–	39.68%	2
2021 Q2	$10.8M	Buy	+642,204	New	+$9.5M	51.19%	1

Other funds holding BRNS

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

GLR Partners Columbia, Maryland $215M AUM

Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

DC Funds's BRNS Position: Q1 2026 in Review

DC Funds held its Barinthus Biotherapeutics (BRNS) position steady in Q1 2026 at 642,204 shares worth $365K. The position accounts for 24.59% of the portfolio, ranked #3.

DC Funds first reported a position in BRNS in Q2 2021 and has held it in 20 quarters since. The position peaked at $10.8M in Q2 2021. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

DC Funds held 642,204 shares of Barinthus Biotherapeutics worth $365K as of Q1 2026.
DC Funds left its Barinthus Biotherapeutics share count unchanged in Q1 2026.
Barinthus Biotherapeutics made up 24.59% of DC Funds's portfolio in Q1 2026, its #3 holding.
DC Funds first reported a position in Barinthus Biotherapeutics in Q2 2021 and has held it in 20 quarters since.
DC Funds's Barinthus Biotherapeutics position peaked at $10.8M in Q2 2021.
14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on DC Funds's 13F filing for Q1 2026, filed 14 May 2026.